Consequently, for tumors with KRAS or BRAF mutations (such as colon and pancreatic cancers) that exhibit high GLUT1 expression and low SVCTs expression, extracellular DHA treatment competitively inhibits glucose uptake by cancer cells. This evidence concerns the gene KRAS and cancer.